Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2024 Diabetes Prevention Awareness Center.